Search - tctmd.com

Displaying 21 - 40 of 58

Sort: Relevancy | Date

News Features EuroPCR 2017

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Yael L. Maxwell

June 01, 2017

Presentation TCT 2014

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

Presenter: Todd J. Brinton, Ian T. Meredith, Greg L. Kaluza, Stefan Verheye

September 16, 2014

Presentation TCT 2014

BRS with Clinical Data I DESolve: Differentiating Features and Clinical Update

Presenter: Alexandre Abizaid, Dean J. Kereiakes, Vasim Farooq, Stefan Verheye

September 16, 2014

Presentation TCT 2014

Acute and chronic effects of cryotherapy on atherosclerotic plaque composition in the thoracic aorta of cholesterol-fed rabbits: a potential solution for treatment of plaques

Presenter: Stefan Verheye

September 16, 2014

Presentation TCT 2014

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Presenter: Marie-Claude Morice, Giulio G. Stefanini, Pedro A. Lemos, Stefan Verheye

September 15, 2014

Presentation TCT 2014

Novolimus-Eluting from a Bioabsorbable Polymer: Latest Update from EXCELLA II

Presenter: Alexandre Abizaid, Pieter C. Smits, Robert J. Gil, Stefan Verheye

September 15, 2014

News Conference News TCT 2014

Novel Biodegradable Polymer DES Shows Efficacy, Long-term Safety

September 15, 2014

News Industry News

Elixir Medical Announces Schedule of Programs for TCT 2014

September 08, 2014

Presentation BRS 2014

DESolve ® Device Description and Clinical Results

Presenter: Stefan Verheye

July 25, 2014

Presentation BRS 2014

Technique Options for BRS in Bifurcations Pros and Cons

Presenter: Stefan Verheye

July 25, 2014

News Industry News

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

May 21, 2014

News Industry News

Elixir Medical Corporation to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

May 14, 2014

News Industry News

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

May 13, 2014

Presentation TCT 2013

TCT-62. Preliminary Result of the Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the Maya Medical OneShot™ Ablation System (RAPID) Study.

Presenter: Stefan Verheye

October 29, 2013

Presentation TCT 2013

Svelte Integrated Delivery System with Enzymatic Bioabsorbable Sirolimus Coating: The DIRECT II Study and Program Update

Presenter: Stefan Verheye

October 27, 2013

Presentation TCT 2013

DESolve Nx Novolimus-Eluting PLLA-Based BRS: First Report of the 6-month OCT and 12-month Clinical and Imaging Results

Presenter: Stefan Verheye

October 27, 2013

News Industry News

InspireMD Announces First Patient Enrolled in U.S. Registration Trial for MGuard™ Prime EPS

July 29, 2013

News Industry News

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

May 01, 2013

Presentation TCT 2013

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

Presenter: Ulf Landmesser, William Wijns, Emanuele Barbato, Pasi Karjalainen, Robbert de Winter, Stefan Verheye, Jonathan Hill, Wojciech Wojakowski, Erik Ligtenberg, Stephen Rowland, Hiram Bezerra, Marco Costa

January 31, 2013

$The Coronary Sinus Reducer – a Device Based Therapy for Refractory Angina; Interim Safety Results of the ongoing COSIRA clinical Trial and efficacy results of the CS Reducer...$

Presentation TCT 2013

The Coronary Sinus Reducer – a Device Based Therapy for Refractory Angina; Interim Safety Results of the ongoing COSIRA clinical Trial and efficacy results of the CS Reducer...

Presenter: Shmuel Banai, Marc Jolicoeur, Jean-Fran?ois Tanguay, Elazer Edelman, Stefan Verheye

January 31, 2013

Advertisement

Seven Next-Generation Bioresorbable Scaffolds Show Promise but Face Major Hurdles

Sirolimus-Eluting Balloon Angioplasty Dilatation System for ISR Indication: The SABRE Trial

BRS with Clinical Data I DESolve: Differentiating Features and Clinical Update

Acute and chronic effects of cryotherapy on atherosclerotic plaque composition in the thoracic aorta of cholesterol-fed rabbits: a potential solution for treatment of plaques

TCT 599: Final Procedural, 30-Day and 6-Month Angiographic, Clinical, and OCT Outcomes from the DIRECT II Trial Using the Svelte Integrated Delivery System with Enzymatic Bioabsobable Sirolimus Coating

Novolimus-Eluting from a Bioabsorbable Polymer: Latest Update from EXCELLA II

Novel Biodegradable Polymer DES Shows Efficacy, Long-term Safety

Elixir Medical Announces Schedule of Programs for TCT 2014

DESolve ® Device Description and Clinical Results

Technique Options for BRS in Bifurcations Pros and Cons

Successful Live Case Demonstration of Elixir Medical’s CE Mark-Approved Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Elixir Medical Corporation to Showcase a Live Case Demonstration of the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System at EuroPCR

Elixir Medical Receives CE Mark Approval for the Breakthrough Fully Bioresorbable DESolve® 100 Novolimus Eluting Coronary Scaffold System

TCT-62. Preliminary Result of the Rapid Renal Sympathetic Denervation for Resistant Hypertension Using the Maya Medical OneShot™ Ablation System (RAPID) Study.

Svelte Integrated Delivery System with Enzymatic Bioabsorbable Sirolimus Coating: The DIRECT II Study and Program Update

DESolve Nx Novolimus-Eluting PLLA-Based BRS: First Report of the 6-month OCT and 12-month Clinical and Imaging Results

InspireMD Announces First Patient Enrolled in U.S. Registration Trial for MGuard™ Prime EPS

Elixir Medical Corporation to Announce 6-month Results of the DESolve Fully Bioresorbable Coronary Scaffold System Pivotal Trial at Late Breaking Trial Session of EuroPCR

The REMEDEE OCT study: A prospective randomized study of the early vascular healing of a novel Dual Therapy Stent in comparison with an everolimus eluting stent

The Coronary Sinus Reducer – a Device Based Therapy for Refractory Angina; Interim Safety Results of the ongoing COSIRA clinical Trial and efficacy results of the CS Reducer...

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content